Vertex Pharma (VRTX) Tops Q1 EPS by 14c; Reiterates Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Vertex (VRTX) PT Raised to $202 at RBC Capital
April 27, 2018 9:01 AM EDTRBC Capital raised its price target on Vertex (NASDAQ: VRTX) to $202.00 (from $199.00) while maintaining a Outperform rating.
... MoreVertex Pharma (VRTX) Begins Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as Triple Combination Regimen for People with Cystic Fibrosis
April 26, 2018 4:37 PM EDTVertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that it is initiating two Phase 3 studies of VX-445, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis (CF). The first Phase 3 study will evaluate approximately 360 people with CF who have one copy of the... More
